Advertisement
Advertisement

CRNX

CRNX logo

Crinetics Pharmaceuticals, Inc.

45.28
USD
Sponsored
+0.49
+1.09%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

45.02

-0.27
-0.59%

CRNX Earnings Reports

Positive Surprise Ratio

CRNX beat 7 of 30 last estimates.

23%

Next Report

Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$4.58M
/
-$1.40
Implied change from Q3 25 (Revenue/ EPS)
+3101.47%
/
+1.45%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+59.09%

Crinetics Pharmaceuticals, Inc. earnings per share and revenue

On Nov 06, 2025, CRNX reported earnings of -1.38 USD per share (EPS) for Q3 25, missing the estimate of -1.28 USD, resulting in a -7.75% surprise. Revenue reached 143.00 thousand, compared to an expected 370.89 thousand, with a -61.44% difference. The market reacted with a -8.02% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -1.40 USD, with revenue projected to reach 4.58 million USD, implying an increase of 1.45% EPS, and increase of 3101.47% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Crinetics Pharmaceuticals, Inc. reported EPS of -$1.38, missing estimates by -7.75%, and revenue of $143.00K, -61.44% below expectations.
The stock price moved down -8.02%, changed from $43.49 before the earnings release to $40.00 the day after.
The next earning report is scheduled for Feb 26, 2026.
Based on 17 analysts, Crinetics Pharmaceuticals, Inc. is expected to report EPS of -$1.40 and revenue of $4.58M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement